Navigation Links
Amyloid imaging helps in evaluating possible Alzheimer disease

Philadelphia, Pa. (November 27, 2012) A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published online by the journal Alzheimer Disease & Associated Disorders. The journal is published by Lippincott Williams & Wilkins, a part ofWolters Kluwer Health.

Positron emission tomography (PET) scans using a biomarker called florbetapir F18 can show amyloid plaques in the braina characteristic feature of AD. "Amyloid imaging results altered physicians' diagnostic thinking, intended testing and management of patients undergoing evaluation for cognitive decline," according to the study by Dr Mark Mintun of Avid Pharmaceuticals, Philadelphia, and colleagues.

Is It Alzheimer Disease? Florbetapir Scan Provides Evidence

The researchers designed a "real-world" study to determine how florbetapir would affect clinical management of patients with cognitive impairment. While a florbetapir PET scan showing amyloid plaques doesn't prove that AD is present, it provides a previously unavailable piece of evidence to support the diagnosis.

The study included 229 patients seen by neurologists or other specialists for evaluation of cognitive decline or impairment of uncertain etiology. Before the florbetapir PET scan, doctors provided a provisional diagnosis, an estimate of their diagnostic confidence, and their plans for further testing and treatment. The goal was to assess the value of florbetapir PET in making the final diagnosis and in providing doctors with useful information for clinical decision making.

The florbetapir PET scans showed amyloid deposits in 113 out of 229 patients. The information provided led doctors to change their diagnosis in 55 percent of cases.

When the provisional diagnosis was AD, imaging results led to a change in diagnosis in 37 percent of cases. When the pre-scan diagnosis was either "indeterminate" or another cause of dementia, the diagnosis changed in over 60 percent of cases. In either direction, the scans increased the physicians' ratings of diagnostic confidence by about 20 percent.

Impact on Treatment and Testing Decisions

Florbetapir PET also provided useful information for treatment decision-making: in 87 percent of patients, the results contributed to at least one change in the treatment plan. The main impact was in deciding whether or not to use medications that are helpful in AD. The scan results also affected decisions on further testingin many cases, physicians dropped plans to perform additional brain imaging studies or neuropsychological tests.

Alzheimer disease is the most common cause of dementia, but the diagnosis can be challenging to make. The only definitive way to diagnose AD is by autopsy examination of the brain after death. Up to 20 percent of patients diagnosed with AD turn out not to have had AD on autopsy, while up to 40 percent of patients diagnosed with other causes of dementia have evidence of AD at autopsy.

Florbetapir PET is the first FDA-approved imaging that can estimate amyloid deposits in the brain of a living patient. Previous studies have shown that the scans are accurate in identifying patients later shown to have AD at autopsy.

The new results show that florbetapir PET scans can have a significant effect in "real world" clinical evaluation of patients with cognitive impairment. By strengthening the case for or against a diagnosis of AD, this test can have a significant impact on patient managementparticularly related to the use of AD medications and the need for further testing. Additional studies will be needed to confirm whether "clinical care that includes amyloid imaging will translate into better outcomes" for patients with cognitive impairment and possible AD.


Contact: Connie Hughes
Wolters Kluwer Health

Related medicine news :

1. BUSM researchers part of multi-center study on cardiac amyloidosis
2. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
3. MR enterography is as good or better than standard imaging exams for pediatric Crohns patients
4. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. Study examines necessity of additional imaging in PET/CT oncologic reports
7. Fox Chase researchers find no disparities in imaging before breast cancer surgery
8. Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting
9. Mount Sinai is first in New York state to perform new Alzheimers imaging test in clinical setting
10. Imaging agents predict breast cancer response to endocrine therapy
11. Noninvasive imaging technique may help kids with heart transplants
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, ... the womb. "My last baby had high blood pressure due to loud noises," she ... protect their babies from noise pollution as well as radio waves and microwaves." , ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... automated breast density assessment and enterprise analytics solutions, here at the 101st ... (South Hall booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... – Kreithen”), one of the leading plastic surgery practices in Florida, is proud ... chosen to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson ...
(Date:11/30/2015)... Morton Grove, IL (PRWEB) , ... November 30, 2015 , ... ... milestone for an emerging pharmaceutical company. Because it is so important to this key ... titled “Success Factors in your IND Filing” on December 4th at 11am EST. , ...
(Date:11/30/2015)... ... 30, 2015 , ... Healthjump, Inc. announced that it has ... consulting, development and support company. The purchase will expand the capability to serve ... extend the services currently provided by Healthjump. , Through this purchase, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... BOSTON , Nov. 30, 2015  Kevin ... of Sensium Healthcare, a global pioneer in wireless ... Boston, MA , Mr. Smith ... of Sensium,s global commercial strategy.  He will also ... universities, to build clinical evidence for SensiumVitals, the ...
(Date:11/30/2015)... , Nov. 30, 2015  The fee-for-service ... in U.S. medical imaging is on its ... accountable care payer-provider contracts are set to ... their wake, alter provider-vendor relationships. The shift ... push forward new purchasing frameworks in the ...
(Date:11/30/2015)... WOODCLIFF LAKE, N.J. and SAN ... Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... (FDA) has accepted for filing the New Drug Application ... approved, the extended release formulation will offer patients a ... ® ) is currently approved as ...
Breaking Medicine Technology: